MarketPeel
Insider Trading Intelligence
Pricing
…
FL

Fairmount Healthcare Fund II L.p.

SYRE
DIRECTOR · SPYRE THERAPEUTICS, INC. · CIK 0001769651
FILING MIX · LIFETIME70%/30%
BUYS
57
SELLS
25
TOTAL VALUE
$1.10B
COMPANIES
8
ACTIVE SINCE
Sep 2021
HOLDINGS NOW
12,517,170
AVG SELL PX
$83.42
TRADE KIND
SHOWING 82 / 82
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
11 backtested trades · 8 horizons · 16 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Fairmount Healthcare Fund II L.p., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d11+100.00%+11.13%+0.47%+10.65%+10.86%—
14d11+54.55%+4.95%+0.14%+4.80%+2.37%—
30d11+54.55%+7.72%+1.34%+6.38%+2.42%—
60d11+45.45%+10.01%+1.63%+9.80%-2.27%—
90d11+36.36%+0.79%+3.56%-2.76%-11.65%—
180d11(2 pending)+55.56%+8.03%+2.72%-7.21%-24.61%—
1y11(6 pending)+40.00%+5.43%+11.02%-5.59%-20.35%—
2y11(8 pending)+66.67%+18.09%+26.83%-8.74%+17.43%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SYRE · 0 shares · as of Jun 23, 2026
01,171,1952,342,3913,513,5864,684,781202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 57 buys / 25 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASE
3,553,410——4,685,364Jul 1, 2026Jul 1, 2026 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
SALE
42,641——94,497Jul 1, 2026Jul 1, 2026 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
SALE
3,553,410$84.43$300.01M1,131,954Jul 1, 2026Jul 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
16,667——0Jun 23, 2026Jun 23, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
4,684,781$85.31$399.66M0Jun 23, 2026Jun 23, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
666,680——4,684,781Jun 23, 2026Jun 23, 2026 ↗View →
JBIO
JADE BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
34,843——34,843Jun 9, 2026Jun 11, 2026 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,136——9,136Jun 2, 2026Jun 3, 2026 ↗View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
11,050——11,050Jun 2, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,026——8,026May 27, 2026May 29, 2026 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
1,176,470$17.00$20.00M5,090,928May 11, 2026May 13, 2026 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
150,000$20.00$3.00M2,359,025Mar 31, 2026Apr 1, 2026 ↗View →
GLTO
GALECTO, INC.
PURCHASEGRANT
Stock grant
37,313——37,313Mar 23, 2026Mar 25, 2026 ↗View →
GLTO
GALECTO, INC.
PURCHASE
2,904,000——2,904,000Feb 9, 2026Feb 12, 2026 ↗View →
GLTO
GALECTO, INC.
PURCHASE
5,809,000——5,809,000Feb 9, 2026Feb 12, 2026 ↗View →
GLTO
GALECTO, INC.
SALE
5,809——1,148Feb 9, 2026Feb 12, 2026 ↗View →
GLTO
GALECTO, INC.
SALE
2,904——574Feb 9, 2026Feb 12, 2026 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE
1,750,000$76.30$133.53M298,647Jan 22, 2026Jan 22, 2026 ↗View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASE
1,360,000$13.41$18.24M2,747,866Dec 4, 2025Dec 8, 2025 ↗View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASE
131,434$13.41$1.76M1,768,140Dec 4, 2025Dec 8, 2025 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
454,545$22.00$10.00M3,914,458Oct 23, 2025Oct 27, 2025 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
316,219$19.00$6.01M2,209,025Oct 7, 2025Oct 9, 2025 ↗View →
JBIO
JADE BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
1,333,126$9.14$12.18M1,897,677Oct 6, 2025Oct 8, 2025 ↗View →
JBIO
JADE BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
855,047$9.14$7.82M855,047Oct 6, 2025Oct 8, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
333,340$15.00$5.00M1,131,954Sep 17, 2025Sep 19, 2025 ↗View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
9,023——9,023Jun 23, 2025Jun 23, 2025 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
12,500$12.31$153.9K3,459,913Jun 10, 2025Jun 11, 2025 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
12,500——0Jun 10, 2025Jun 11, 2025 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
18,500——18,500Jun 10, 2025Jun 12, 2025 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
1,600$7.80$12.5K3,447,413Jun 9, 2025Jun 11, 2025 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
1,600——0Jun 9, 2025Jun 11, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,500——17,500Jun 2, 2025Jun 3, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000May 29, 2025Jun 2, 2025 ↗View →
JBIO
JADE BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
23,017——23,017Apr 29, 2025May 1, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
SALE
160——0Nov 19, 2024Nov 21, 2024 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASE
160,000——798,614Nov 19, 2024Nov 21, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
SALE
357,143——0Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
SALE
2,614,287——0Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
300,000$17.00$5.10M1,892,806Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
SALE
2,195,871——0Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
709,794——1,291,729Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
301,077——1,592,806Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
SALE
6,163,236——0Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
252,890——581,935Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
41,130——329,045Sep 16, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
SALE
2,195,871——0Sep 16, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
301,077——1,304,891Sep 16, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
300,000$17.00$5.10M1,604,891Sep 16, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
SALE
6,163,236——0Sep 16, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
252,890——294,020Sep 16, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
SALE
357,143——0Sep 16, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
709,794——1,003,814Sep 16, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
SALE
2,614,287——0Sep 16, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASE
41,130——41,140Sep 16, 2024Sep 16, 2024 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
1,600,000$18.75$30.00M3,445,813Sep 13, 2024Sep 17, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
37,000——37,000Sep 12, 2024Sep 16, 2024 ↗View →
ZBIO
ZENAS BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
37,000——37,000Sep 12, 2024Sep 17, 2024 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
275,000$23.00$6.33M638,614Sep 11, 2024Sep 13, 2024 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
160$23,000.00$3.68M160Sep 11, 2024Sep 13, 2024 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
3,639,680——4,018,101Apr 25, 2024Apr 25, 2024 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
90,992——346,045Apr 25, 2024Apr 25, 2024 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
5,859——1,845,813Mar 28, 2024Apr 1, 2024 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
21,999——133,191Mar 28, 2024Apr 1, 2024 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
5,859——0Mar 28, 2024Apr 1, 2024 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
21,999——0Mar 28, 2024Apr 1, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE
55,913——0Mar 28, 2024Apr 1, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASE
55,913——2,048,647Mar 28, 2024Apr 1, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE
221,426——0Mar 28, 2024Apr 1, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASE
221,426——6,743,321Mar 28, 2024Apr 1, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
SALE
892,529——0Jan 29, 2024Jan 31, 2024 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASE
51,166——51,166Jan 29, 2024Jan 31, 2024 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
476,190$21.00$10.00M1,839,954Jan 22, 2024Jan 24, 2024 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
3,435,480——0Dec 29, 2023Dec 29, 2023 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
406,038——406,038Dec 29, 2023Dec 29, 2023 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,667$600.00$10.00M16,667Dec 7, 2023Dec 11, 2023 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
48,463$825.37$40.00M48,463Oct 30, 2023Nov 1, 2023 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASE
1,992,734$17.00$33.88M1,992,734Jul 13, 2023Jul 17, 2023 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASE
892,529$17.00$15.17M892,529Jul 13, 2023Jul 17, 2023 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASE
55,913$17.00$950.5K55,913Jul 13, 2023Jul 17, 2023 ↗View →
APGE
APOGEE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
47,758——47,758Jul 13, 2023Jul 17, 2023 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
425,531$23.50$10.00M1,363,764Aug 17, 2022Aug 19, 2022 ↗View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
909,000$11.00$10.00M938,233Sep 21, 2021Sep 23, 2021 ↗View →
Other insiders · SYRE
Loading peer insiders…
About this filer
CIK 0001769651
ROLE
Director
PRIMARY
SYRE
COMPANIES
8
ACTIVE SINCE
Sep 2021
MARKETPEEL · /INSIDER/0001769651DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback